These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 27075022)
1. Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013. Kinlaw AC; Jonsson Funk M; Steiner MJ; Conover MM; Pate V; Wu JM Clin Pediatr (Phila); 2017 Jan; 56(1):55-64. PubMed ID: 27075022 [TBL] [Abstract][Full Text] [Related]
2. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. Wagg A; Compion G; Fahey A; Siddiqui E BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769 [TBL] [Abstract][Full Text] [Related]
3. Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment. Vouri SM; Schootman M; Strope SA; Birge SJ; Olsen MA Drugs Aging; 2018 Apr; 35(4):321-331. PubMed ID: 29492862 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546 [TBL] [Abstract][Full Text] [Related]
5. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386 [TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related]
8. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724 [TBL] [Abstract][Full Text] [Related]
9. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients. Yoshida M; Kato D; Nishimura T; Van Schyndle J; Uno S; Kimura T Int J Urol; 2018 Oct; 25(10):855-862. PubMed ID: 30069973 [TBL] [Abstract][Full Text] [Related]
10. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055 [TBL] [Abstract][Full Text] [Related]
11. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Kachru N; Sura S; Chatterjee S; Aparasu RR Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701 [TBL] [Abstract][Full Text] [Related]
12. Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study. Green AR; Segal J; Boyd CM; Huang J; Roth DL Drugs Real World Outcomes; 2020 Jun; 7(2):151-159. PubMed ID: 32052322 [TBL] [Abstract][Full Text] [Related]
13. Association of Health Care Utilization With Rates of Perforated Appendicitis in Children 18 Years or Younger. Baxter KJ; Nguyen HTMH; Wulkan ML; Raval MV JAMA Surg; 2018 Jun; 153(6):544-550. PubMed ID: 29387882 [TBL] [Abstract][Full Text] [Related]
14. Secular trends of antibacterial prescribing in UK paediatric primary care. Schneider-Lindner V; Quach C; Hanley JA; Suissa S J Antimicrob Chemother; 2011 Feb; 66(2):424-33. PubMed ID: 21172784 [TBL] [Abstract][Full Text] [Related]
15. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. Margulis AV; Linder M; Arana A; Pottegård A; Berglind IA; Bui CL; Kristiansen NS; Bahmanyar S; McQuay LJ; Atsma WJ; Appenteng K; D'Silva M; Perez-Gutthann S; Hallas J PLoS One; 2018; 13(9):e0204456. PubMed ID: 30260993 [TBL] [Abstract][Full Text] [Related]
16. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries. LaVange LM; Silverman HA Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516 [TBL] [Abstract][Full Text] [Related]
18. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Garely AD; Burrows L Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509 [TBL] [Abstract][Full Text] [Related]
19. Metformin prescription patterns among US adolescents aged 10-19 years: 2009-2013. Wang T; McNeill AM; Chen Y; Senderak M; Shankar RR J Clin Pharm Ther; 2016 Apr; 41(2):229-36. PubMed ID: 26960965 [TBL] [Abstract][Full Text] [Related]
20. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions. Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]